NCT04164199 2026-03-16Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesBeOne MedicinesPhase 3 Enrolling by invitation430 enrolled
NCT06540144 2026-02-27An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisUCB PharmaPhase 3 Enrolling by invitation12 enrolled